0
0
A pioneering clinical study has revealed that replacing dysfunctional brain cells with healthy donor cells can slow, and potentially halt, the progression of a rare neurodegenerative disorder, offering hope for future treatments of other neurological diseases.
Researchers focused on adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a devastating rare disease that strikes in middle age and shortens life expectancy to just 3–5 years after symptoms appear. ALSP is caused by mutations in the CSF1R gene, which disrupt the development and function of microglia—critical immune cells within the brain.
A small-scale study involving eight ALSP patients tested whether bone marrow transplants (BMT) from healthy donors could replace the faulty microglia found in these individuals. Results have been striking: the procedure halted neurological decline, maintained motor functions, and stabilized cognitive abilities over a two-year follow-up period. In contrast, individuals with the disease who did not receive this therapy experienced a much faster deterioration.
The innovative approach builds on earlier experimental work in animal models showing that transplanting normal microglia can reverse key disease features, such as myelin damage and motor impairments. Fascinatingly, the inherent genetic deficit in ALSP patients gives donor cells a competitive advantage in taking over from the native, impaired microglia, making traditional BMT sufficiently effective without further interventions.
The researchers point to broader applications ahead. Since microglial dysfunction is a feature of several neurodegenerative diseases—most notably Alzheimer’s—this cell replacement strategy could one day benefit a much wider patient population.
Experts unaffiliated with the study praised its demonstration that correcting a microglial gene defect through cell replacement can profoundly influence disease progression in humans, marking a vital step toward developing such therapies for other monogenic neurological disorders. Ongoing clinical trials will further test the durability and safety of this approach, as well as refine methods to optimize donor cell integration and minimize risks.
While these initial findings are encouraging, the therapy remains in early stages. Researchers caution that larger trials are necessary to validate the results and that widespread clinical use could be years away, dependent on continued success, demonstrated long-term safety, and regulatory approvals.
Future strategies will also need to address issues such as optimizing donor cell sourcing, minimizing systemic side effects from transplant conditioning, and ensuring the functional competence of engrafted cells.
This news article is based on early-stage research findings. The therapies discussed are not yet widely available and are undergoing further clinical evaluation. Patients should consult qualified healthcare professionals before considering any experimental treatment options. The results described pertain solely to the clinical study referenced and may not be broadly applicable or indicative of outcomes for other individuals or conditions1.
